Articles On Medadvisor (ASX:MDR)
Title | Source | Codes | Date |
---|---|---|---|
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends
Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week When we talk about dividend-paying hea... |
Stockhead | MDR | 1 year ago |
MoneyTalks: Why Salter Brothers is eyeing ASX small cap medtechs
MoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to hear what’s hot, their top picks, and what they’re looking out for. Today we hear from Salter Broth... |
Stockhead | MDR | 1 year ago |
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough
Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May There are clear signs the biotech sector is springing back to life after a disappointing 2... |
Stockhead | MDR | 1 year ago |
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales
Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s... |
Stockhead | MDR | 1 year ago |
Dr Boreham’s Crucible: Are MedAdvisor’s US plans about to go to script?
Despite the billions of dollars spent on developing new drugs, many of them are ineffective for a large number of patients. Is that a Big Pharma conspiracy to be revealed on the ABC’s Four Corners next Monday night? Er – no, actually. The... |
Stockhead | MDR | 1 year ago |
Medadvisor [ASX:MDR] Transitions Back into Profit for Half-Year 2023
Medadvisor [ASX:MDR], Australian developer of healthcare software for patients, announced its return back into profit in its half-year 2023 results announcement — declaring profits had surged 161%. Investors were tipping the MDR share price... |
Daily Reckoning | MDR | 1 year ago |
Top 10 at 10: Which ASX stocks are flying and floundering on Friday?
Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | MDR | 1 year ago |
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care
The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry The US FDA announced last week that:... |
Stockhead | MDR | 1 year ago |
Top 10 at 10: Which ASX exploration stocks are hitting paydirt today?
Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | MDR | 1 year ago |
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device
Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past... |
Stockhead | MDR | 1 year ago |
ASX December Winners: Who’s led the way for small caps in tough month for global markets?
Little joy for investors in December with traditional Christmas rally not eventuating in 2022 Meteoric Resources leads December winners after positive metallurgical results at its new Caldeira project. Symbio Holdings saw its share price p... |
Stockhead | MDR | 1 year ago |
ASX Director Trades: Which Meteoric Resources director buys up big in the December winner?
December winner Meteoric Resources sees a non-executive director buy 6 million shares Northern Star Resources and Chalice Mining directors sell in December for tax obligations Johns Lyng Group COO Lindsay Barber sells 4 million shares, ~3... |
Stockhead | MDR | 1 year ago |
5 things to watch on the ASX 200 on Thursday
On Wednesday, the S&P/ASX 200 Index (ASX: XJO) was back on form and charged notably higher. The benchmark index rose 1.3 % to 7,115.1 points. Will the market be able to build on this on Thursday? Here are five things to watch: ASX 20... |
Motley Fool | MDR | 1 year ago |
Could ASX 200 gold shares be ‘at another pivot point’?
ASX 200 gold shares soared on Wednesday, but could a ‘pivot point’ for the gold price be on the way? Gold producers on the ASX 200 include Evolution Mining Ltd (ASX: EVN), Newcrest Mining Ltd (ASX: NCM), and Northern Star Resources Lt... |
Motley Fool | MDR | 1 year ago |
Here are the top 10 ASX 200 shares today
The S&P/ASX 200 Index (ASX: XJO) bounced back from yesterdayâs chaos today. The index closed 1.3% higher at 7,115.1 points. Leading todayâs gains on the Aussie bourse was the S&P/ASX 200 Utilities Index (ASX: XUJ). It rose 3.8%... |
Motley Fool | MDR | 1 year ago |
Here are the 3 most heavily traded ASX 200 shares on Wednesday
The S&P/ASX 200 Index (ASX: XJO) has shaken off the malaise that has been gripping it this week and posted a strong gain at this point of Wednesday’s trading session. At the time of writing, the ASX 200 has gained a very healthy 1.35%,... |
Motley Fool | MDR | 1 year ago |
Why are ASX 200 gold shares having such a stellar run today?
ASX 200 gold shares are having a top run on the market today amid higher gold prices. Gold explorers in the green include Evolution Mining Ltd (ASX: EVN), Newcrest Mining Ltd (ASX: NCM) and Northern Star Resources Ltd (ASX: NST) Let’s tak... |
Motley Fool | MDR | 1 year ago |
Why you should pay attention to the Bank of Japan
Investors were caught off guard yesterday after the Bank of Japan (BoJ) broke decades of monetary tradition. The central bank’s decision to widen the acceptable band on the country’s risk-free rate was met with blood in equity markets. In... |
Motley Fool | MDR | 1 year ago |
Why European Lithium, Evolution, Medadvisor, and REA shares are charging higher
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has bounced back from yesterdayâs selloff. At the time of writing, the benchmark index is up 1.3% to 7,117.2 points. Four ASX shares that are climbing more than most today are lis... |
Motley Fool | MDR | 1 year ago |
Stocks of the Hour: Matrix Composites & Engineering, DroneShield, MedAdvisor
21 Dec 2022 - A snapshot of the stocks on the move featuring Matrix Composites & Engineering (ASX:MCE), DroneShield (ASX:DRO) and MedAdvisor (ASX:MDR). |
FNN | MDR | 1 year ago |
MedAdvisor expects 50-60% revenue growth as US expansion accelerates
This content is created by Smallcaps Authors. [Author : Lorna Nicholas] MedAdvisor (ASX: MDR) has revealed it expects revenue for the six months ending December 2022 (H1 FY2023) to be up 50-60% on H1 FY2022 levels due to the company’s US... |
SmallCaps | MDR | 1 year ago |
MedAdvisor’s US digital strategy set to boost first-half revenue by up to 60pc
An acquisitive couple of years is starting to pay off for pharmacy tech company MedAdvisor (ASX: MDR) which has forecast a spike of between 50 and 60 per cent in first-half revenue for FY23. MedAdvisor is expecting revenue to land between... |
businessnewsaustralia.com | MDR | 1 year ago |
Market Highlights: Oh, BoJ, what have you done… and 5 ASX small caps to watch today
Markets overnight were scrambling to adjust to a shock move by the Bank of Japan to allow the yield on 10-year Japanese government bonds to shift up to 0.50 per cent instead of its long-preferred 0.25 per cent cap. In a nutshell, Japan’s be... |
Stockhead | MDR | 1 year ago |
How out of favour Biotech has a PR problem and could learn from Dr Karl
ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and... |
Stockhead | MDR | 1 year ago |
Check Up: Only two healthcare IPOs from 2021 are gaining ground, could the rest be buying opportunities?
We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month There were 191 ASX IPOs in... |
Stockhead | MDR | 2 years ago |
3 ASX healthcare shares punished following full-year results
ASX healthcare shares have been a mixed bag this earnings season, with some names completely blowing it out of the park, whereas others have left more to be desired. The S&P/ASX 200 Health Care index (ASX: XHJ) finished up 122 basis p... |
Motley Fool | MDR | 2 years ago |
MoneyTalks: 3 ‘below-the-radar’ ASX stocks to watch in the second half of 2022
MoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to hear what’s hot, their top picks, and what they’re looking out for. Today we hear from Equitable In... |
Stockhead | MDR | 2 years ago |
Closing Bell: Rumours so ripe and markets so flat that everyone’s in a trading halt
ASX 200 is flat Small Caps index is flatter, let’s call it tepid Lots of fun rumours to dissect So the Hang Seng Tech index lost nearly 2% when it opened this morning. And while most major indices across the Asia-Pacific ‘hood were inde... |
Stockhead | MDR | 2 years ago |
MedAdvisor (ASX:MDR) enters trading halt ahead of $14.6m capital raise and GuildLink acquisition
MedAdvisor (MDR) enters into a trading halt ahead of a $14.6 million capital raise to support accelerated growth and the planned acquisition of GuildLink The acquisition of GuildLink will enable MedAdvisor to provide a consolidated platfor... |
themarketherald.com.au | MDR | 2 years ago |
ASX 200 opens up; IT and Financial sectors lead gains
Highlights: The S&P/ASX200 opened a little higher today (July 25). ASX 200 has been taking cues from the Wall Street which closed on a mixed note on Friday. Ten out of eleven sectors on the ASX opened up strong today. The S&am... |
Kalkine Media | MDR | 2 years ago |
ASX 200 opens up; IT and Financial sectors lead gains
Highlights: The S&P/ASX200 opened a little higher today (July 25). ASX 200 has been taking cues from the Wall Street which closed on a mixed note on Friday. Ten out of eleven sectors on the ASX opened up strong today. The S&am... |
Kalkine Media | MDR | 2 years ago |
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs
US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F... |
Stockhead | MDR | 2 years ago |
Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit
A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m... |
Stockhead | MDR | 2 years ago |
MedAdvisor (ASX:MDR) appoints US-based CEO and MD, Rick Ratliff
MedAdvisor (MDR) appoints US-based CEO and Managing Director, Rick Ratliff In April, current CEO and MD Robert Read announced his intention to retire from the role as he wasn’t prepared to move to the US, in line with the company’s growth... |
themarketherald.com.au | MDR | 2 years ago |
ASX Health Stocks: Antisense says ATL1102 could be effective in rare genetic muscle disease
Antisense announces positive study of ATL1102 Acrux to launch a new product in the US MedAdvisor gets new CEO Antisense Therapeutics (ASX:ANP) announced a successful study into a new muscle disease indication for its lead drug, ATL1102.... |
Stockhead | MDR | 2 years ago |
Check Up: Money managers are still bullish on Healthcare; here’s what they said
The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week Dr Anthony Faucci, America’s top infectious disea... |
Stockhead | MDR | 2 years ago |
Check Up: Biotechs are going through a rough patch, but recent ASX IPOs haven’t flopped too badly
The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot... |
Stockhead | MDR | 2 years ago |
MedAdvisor (ASX:MDR) sees CEO transition in line with US growth plans
MedAdvisor’s (MDR) CEO and Managing Director, Robert Read, intends to retire from his role as the company shifts its focus towards growth in the US Mr Read says he’s unable to commit to relocating to the US due to family reasons and he and... |
themarketherald.com.au | MDR | 2 years ago |
ASX Health Stocks: Rhythm Bio surprises with major announcement on ColoSTAT
Rhythm Biosciences releases positive results of ColoSTAT MedAdvisor’s acquisition Adheris exceeds revenue target In a major development today, Rhythm Biosciences (ASX:RHY) was up 15% after announcing that its blood test product ColoSTAT e... |
Stockhead | MDR | 2 years ago |
Check Up: More clinical trials and FDA funding boost. Is this the end of biotech’s woes?
Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve... |
Stockhead | MDR | 2 years ago |
Check Up: The future of telehealth, and the best and worst performing ASX health stocks for the month
Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal... |
Stockhead | MDR | 2 years ago |
ASX Health Stocks: Results show revenue is growing in first half, but profitability still elusive
The ASX 200 Health Index (XHJ) is trading higher by 0.27% at the time of writing, compared to the broader index which is trading flat. More half year earnings results were announced this morning. Here’s a recap and highlight on where things... |
Stockhead | MDR | 2 years ago |
MedAdvisor (ASX:MDR) enters New Zealand market
Medtech company MedAdvisor (MDR) enters the New Zealand market via a three-year agreement with Green Cross Health Green Cross Health is a provider of primary health care services in New Zealand and represents 350 community pharmacies under... |
themarketherald.com.au | MDR | 2 years ago |
Check Up: Johnson & Johnson manoeuvre causes a stir, as CSL pulls Healthcare higher on the ASX
The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby... |
Stockhead | MDR | 2 years ago |
Check Up: As Omicron rages, rapid antigen testing specialist Atomo surges nearly 50pc
At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform... |
Stockhead | MDR | 2 years ago |
Check Up: Anteotech riding high with $1.9m refund, and Avecho inks supply agreement for CBD arthritis treatment
It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining. Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %... |
Stockhead | MDR | 2 years ago |
Check Up: Neuren close to FDA drug approval and Compumedics fires up Aussie factory for medical wearables
It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining. Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont... |
Stockhead | MDR | 2 years ago |
ASX Health Stocks: Health app MedAdvisor maintains guidance, but share price slips 5pc
The ASX 200 Health Index (XHJ) is down by 0.70% at the time of writing, compared to the broader index which is down by 0.55%. Health tech MedAdvisor (ASX:MDR) held its AGM this morning, in which it outlined the company’s strategic prioritie... |
Stockhead | MDR | 2 years ago |
Check Up: Sustainable Nutrition riding high and Singular Health branches out from… health
It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining. Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M... |
Stockhead | MDR | 2 years ago |
Reporting Season Round Up: Leading the charge was Playside – the ASX’s local games developer
Today’s top stock was Playside Studios (ASX:PLY), the only ASX listed e-sports developer that’s based in Australia. Playside Studios (ASX:PLY) Playside is also the newest listed ASX company in this space, debuting last December at 20 cent... |
Stockhead | MDR | 3 years ago |